Editas Medicine price target lowered to $8 from $12 at Truist

Truist analyst Joon Lee lowered the firm’s price target on Editas Medicine (EDIT) to $8 from $12 and keeps a Buy rating on the shares. The company will share updated reni-cel data at ASH, along with updates on in vivo program, in Q1, though the drug may need more than clinical differentiation to succeed commercially, the analyst tells investors in a research note. Truist adds that Editas should catch up in valuation to its peers thanks to its senior party position in the ongoing U.S. patent litigation, which could continue to favor the company in the U.S.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on EDIT:

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.